Galectin Therapeutics (GALT) says new clinical trial data disclosed Thursday suggest its experimental cancer drug improves the efficacy of Merck’s blockbuster immunotherapy therapy Keytruda when the two drugs are used together to treat patients with advanced melanoma.
No, the new Galectin data — what little there are — show no such thing. It’s more reasonable to conclude these new data show Galectin’s drug to be a placebo.
Galectin is a small biotech company, headquartered in a north Atlanta suburb, with a reputation going back years for making overly promotional claims about its drug pipeline. Most recently, Galectin has been trying to sell investors on the idea that its experimental drug, GR-MD-02, could be effective against two disparate diseases — the chronic fatty liver disease known as NASH and cancer.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
